5. Saltini C, Krotova K. Mechanisms of lung disease. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 52–63. 6. Barrecheguren M, Bals R, Miravittles M. Clinical approach to diagnosis and assessment. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 64–77. 7. Teckman JH, Patel D. Clinical approach to paediatric liver disease. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 105–113. 8. Strnad P, Schneider CV, Clark V. Clinical approach to liver disease in adults. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 114–126. 9. Franciosi AN, Carroll TP, McElvaney NG. Rare manifestations. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 127–142. 10. Wilkens M, Hannah T. Patient view. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 1–5. 11. Ellis P, Dirksen A, Turner AM. Treatment of lung disease. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 78–92. 12. Chorostowska-Wynimko J, Jezela-Stanek A. Genetic counselling. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 143–149. 13. Schouten IGM, Stolk J, Fuge J, et al. Registries: roles, objectives and registry data study outcomes. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 150–158. 14. Janciauskiene S, Welte T. Future directions: diagnostic approaches and therapy with AAT. In: Strnad P, Brantly ML, Bals R, eds. ɑ1-Antitrypsin Deficiency (ERS Monograph). Sheffield, European Respiratory Society, 2019 pp. 159–178. Disclosures: P. Strnad reports receiving research support, consultation fees and/or speaker honoraria from Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, CSL Behring and Grifols Inc. R. Bals reports receiving the following, outside the submitted work: grants and personal fees from AstraZeneca, Boehringer Ingelheim and Novartis personal fees from GlaxoSmithKline, Grifols and CSL Behring and grants from the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Sander Stiftung, Schwiete Stiftung, Krebshilfe and Mukoviszidose eV. https://doi.org/10.1183/2312508X.10026219 xi